Skip to main content
Erschienen in: Cancer Causes & Control 5/2017

14.03.2017 | Original paper

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

verfasst von: Albina N. Minlikeeva, Jo L. Freudenheim, Rikki A. Cannioto, J. Brian Szender, Kevin H. Eng, Francesmary Modugno, Roberta B. Ness, Michael J. LaMonte, Grace Friel, Brahm H. Segal, Kunle Odunsi, Paul Mayor, Emese Zsiros, Barbara Schmalfeldt, Rüdiger Klapdor, Thilo Dӧrk, Peter Hillemanns, Linda E. Kelemen, Martin Kӧbel, Helen Steed, Anna de Fazio, Susan J. Jordan, Christina M. Nagle, Harvey A. Risch, Mary Anne Rossing, Jennifer A. Doherty, Marc T. Goodman, Robert Edwards, Keitaro Matsuo, Mika Mizuno, Beth Y. Karlan, Susanne K. Kjær, Estrid Høgdall, Allan Jensen, Joellen M. Schildkraut, Kathryn L. Terry, Daniel W. Cramer, Elisa V. Bandera, Lisa E. Paddock, Lambertus A. Kiemeney, Leon F. Massuger, Jolanta Kupryjanczyk, Andrew Berchuck, Jenny Chang-Claude, Brenda Diergaarde, Penelope M. Webb, Kirsten B. Moysich, on behalf of the Australian Ovarian Cancer Study Group, on behalf of the Ovarian Cancer Association Consortium

Erschienen in: Cancer Causes & Control | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.

Methods

Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.

Results

History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01–1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88–1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87–1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35–0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03–1.40, HR = 1.28; 95% CI = 1.05–1.55, and HR = 1.63; 95% CI = 1.20–2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53–0.94.

Conclusions

Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.
Literatur
1.
2.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, Global cancer statistics, 2012. CA Cancer J Clin, 65 (2015) 87–108 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, Global cancer statistics, 2012. CA Cancer J Clin, 65 (2015) 87–108
3.
4.
Zurück zum Zitat Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10CrossRefPubMed Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10CrossRefPubMed
5.
Zurück zum Zitat Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S (1993) Age as a prognostic factor in ovarian carcinoma. The gynecologic oncology group experience. Cancer 71:606–614CrossRefPubMed Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S (1993) Age as a prognostic factor in ovarian carcinoma. The gynecologic oncology group experience. Cancer 71:606–614CrossRefPubMed
6.
Zurück zum Zitat Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, Griffiths RI (2013) Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol 129:346–352CrossRefPubMed Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, Griffiths RI (2013) Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol 129:346–352CrossRefPubMed
7.
Zurück zum Zitat Bakhru A, Buckanovich RJ, Griggs JJ (2011) The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 121:106–111CrossRefPubMed Bakhru A, Buckanovich RJ, Griggs JJ (2011) The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 121:106–111CrossRefPubMed
8.
Zurück zum Zitat Richardson LC, Pollack LA (2005) Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2:48–53CrossRefPubMed Richardson LC, Pollack LA (2005) Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2:48–53CrossRefPubMed
9.
Zurück zum Zitat Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9:4514–4521PubMed Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9:4514–4521PubMed
10.
Zurück zum Zitat Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12:369–375CrossRefPubMedPubMedCentral Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12:369–375CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ferriss JS, Ring K, King ER, Courtney-Brooks M, Duska LR, Taylor PT (2012) Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer? Int J Gynecol Cancer 22:762–769CrossRefPubMed Ferriss JS, Ring K, King ER, Courtney-Brooks M, Duska LR, Taylor PT (2012) Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer? Int J Gynecol Cancer 22:762–769CrossRefPubMed
12.
Zurück zum Zitat Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Gale EA, Patterson CC, Keen H (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92:2070–2075CrossRefPubMedPubMedCentral Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Gale EA, Patterson CC, Keen H (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92:2070–2075CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 120:1986–1992CrossRefPubMed van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 120:1986–1992CrossRefPubMed
14.
Zurück zum Zitat Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Jonsson H, Häggström C, Stattin P, Engeland A (2011) Metabolic risk factors and ovarian cancer in the metabolic syndrome and cancer project. Int J Epidemiol 40:1667–1677CrossRefPubMed Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Jonsson H, Häggström C, Stattin P, Engeland A (2011) Metabolic risk factors and ovarian cancer in the metabolic syndrome and cancer project. Int J Epidemiol 40:1667–1677CrossRefPubMed
15.
Zurück zum Zitat Stocks T, Van Hemelrijck M, Manjer J, Bjørge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P (2012) Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 59:802–810CrossRefPubMed Stocks T, Van Hemelrijck M, Manjer J, Bjørge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P (2012) Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 59:802–810CrossRefPubMed
16.
Zurück zum Zitat Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55:231–240CrossRefPubMed Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55:231–240CrossRefPubMed
17.
Zurück zum Zitat Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:885–891PubMed Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:885–891PubMed
18.
Zurück zum Zitat Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML (2005) The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97, 104–109CrossRefPubMed Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML (2005) The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97, 104–109CrossRefPubMed
19.
Zurück zum Zitat Sperling C, Noer MC, Christensen IJ, Nielsen ML, Lidegaard O, Hogdall C (2013) Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecol Oncol 129:97–102CrossRefPubMed Sperling C, Noer MC, Christensen IJ, Nielsen ML, Lidegaard O, Hogdall C (2013) Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecol Oncol 129:97–102CrossRefPubMed
20.
Zurück zum Zitat Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK (2015) Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121:3444–3451CrossRefPubMedPubMedCentral Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK (2015) Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121:3444–3451CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127:375–378CrossRefPubMed Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127:375–378CrossRefPubMed
22.
Zurück zum Zitat Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, Lemeshow S (2013) Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer 13:85CrossRefPubMedPubMedCentral Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, Lemeshow S (2013) Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer 13:85CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Eskander R, Bessonova L, Chiu C, Ward K, Culver H, Harrison T, Randall L (2012) Beta blocker use and ovarian cancer survival. Gynecol Oncol 121, S21CrossRef Eskander R, Bessonova L, Chiu C, Ward K, Culver H, Harrison T, Randall L (2012) Beta blocker use and ovarian cancer survival. Gynecol Oncol 121, S21CrossRef
24.
Zurück zum Zitat Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case–control study. Am J Epidemiol 144:363–372CrossRefPubMed Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case–control study. Am J Epidemiol 144:363–372CrossRefPubMed
25.
Zurück zum Zitat L.E. Kelemen, M. Köbel, A. Chan, S. Taghaddos, I. Dinu(2013) Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue. Biomed Res Int 2013, 815894CrossRefPubMedPubMedCentral L.E. Kelemen, M. Köbel, A. Chan, S. Taghaddos, I. Dinu(2013) Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue. Biomed Res Int 2013, 815894CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat KöbelM, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE, A.S. Group (2014) Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 111:2297–2307 KöbelM, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE, A.S. Group (2014) Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 111:2297–2307
27.
Zurück zum Zitat Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176CrossRefPubMed Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176CrossRefPubMed
28.
Zurück zum Zitat Risch HA, Bale AE, Beck PA, Zheng W (2006) PGR + 331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Prev Biomark 15:1738–1741CrossRef Risch HA, Bale AE, Beck PA, Zheng W (2006) PGR + 331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Prev Biomark 15:1738–1741CrossRef
29.
Zurück zum Zitat Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control 23:1985–1994CrossRefPubMedPubMedCentral Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control 23:1985–1994CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Prev Biomark 16:2548–2556CrossRef Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Prev Biomark 16:2548–2556CrossRef
31.
Zurück zum Zitat Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95:370–374CrossRefPubMed Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95:370–374CrossRefPubMed
32.
Zurück zum Zitat Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME (2008) Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Cancer 15:1055–1060CrossRefPubMedPubMedCentral Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME (2008) Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Cancer 15:1055–1060CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243CrossRefPubMed Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243CrossRefPubMed
34.
Zurück zum Zitat Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB (2012) Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 23:311–319CrossRefPubMedPubMedCentral Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB (2012) Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 23:311–319CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Hamajima N, Matsuo K, Saito T, Hirose K, Inoue M, Takezaki T, Kuroishi T, Tajima K (2001) Gene-environment interactions and polymorphism studies of cancer risk in the hospital-based epidemiologic research program at Aichi cancer center II (HERPACC-II). Asian Pac J Cancer Prev 2:99–107PubMed Hamajima N, Matsuo K, Saito T, Hirose K, Inoue M, Takezaki T, Kuroishi T, Tajima K (2001) Gene-environment interactions and polymorphism studies of cancer risk in the hospital-based epidemiologic research program at Aichi cancer center II (HERPACC-II). Asian Pac J Cancer Prev 2:99–107PubMed
36.
Zurück zum Zitat Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164:2253–2259CrossRefPubMed Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164:2253–2259CrossRefPubMed
37.
Zurück zum Zitat Soegaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Prev Biomark 16:1160–1166CrossRef Soegaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Prev Biomark 16:1160–1166CrossRef
38.
Zurück zum Zitat Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A (2010) Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS ONE 5:e10061CrossRefPubMedPubMedCentral Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A (2010) Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS ONE 5:e10061CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A (2008) Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Prev Biomark 17:585–593CrossRef Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A (2008) Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Prev Biomark 17:585–593CrossRef
40.
Zurück zum Zitat Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW (2005) Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65:5974–5981CrossRefPubMedPubMedCentral Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW (2005) Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65:5974–5981CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL (2013) Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 28:1406–1417CrossRefPubMedPubMedCentral Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL (2013) Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 28:1406–1417CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH (2011) Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Womens Health 11:40CrossRefPubMedPubMedCentral Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH (2011) Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Womens Health 11:40CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Gifkins D, Olson SH, Paddock L, King M, Demissie K, Lu SE, Kong AN, Rodriguez-Rodriguez L, Bandera EV (2012) Total and individual antioxidant intake and risk of epithelial ovarian cancer. BMC Cancer 12:211CrossRefPubMedPubMedCentral Gifkins D, Olson SH, Paddock L, King M, Demissie K, Lu SE, Kong AN, Rodriguez-Rodriguez L, Bandera EV (2012) Total and individual antioxidant intake and risk of epithelial ovarian cancer. BMC Cancer 12:211CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Chandran U, Bandera EV, Williams-King MG, Paddock LE, Rodriguez-Rodriguez L, Lu SE, Faulkner S, Pulick K, Olson SH (2011) Healthy eating index and ovarian cancer risk. Cancer Causes Control 22:563–571CrossRefPubMedPubMedCentral Chandran U, Bandera EV, Williams-King MG, Paddock LE, Rodriguez-Rodriguez L, Lu SE, Faulkner S, Pulick K, Olson SH (2011) Healthy eating index and ovarian cancer risk. Cancer Causes Control 22:563–571CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Beesley J, Webb PM, Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD, W.T.C.-C. Consortium, A.C.S.O. Cancer, A.O.C.S. Group, O.C.A.C. OCAC (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42:874–879 Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Beesley J, Webb PM, Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD, W.T.C.-C. Consortium, A.C.S.O. Cancer, A.O.C.S. Group, O.C.A.C. OCAC (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42:874–879
46.
Zurück zum Zitat Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA, A.O.C.S. Group, A.C.S.O. Cancer, O.C.A. Consortium (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42:880–884 Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA, A.O.C.S. Group, A.C.S.O. Cancer, O.C.A. Consortium (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42:880–884
47.
Zurück zum Zitat Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J (2010) A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet 11:20CrossRefPubMedPubMedCentral Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J (2010) A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet 11:20CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M, Polish Ovarian Cancer Study Group (POCSG) (2008) TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer 8:27CrossRefPubMedPubMedCentral Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M, Polish Ovarian Cancer Study Group (POCSG) (2008) TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer 8:27CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat O’Malley CD, Cress RD, Campleman SL, Leiserowitz GS (2003) Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study. Gynecol Oncol 91:608–615CrossRefPubMed O’Malley CD, Cress RD, Campleman SL, Leiserowitz GS (2003) Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study. Gynecol Oncol 91:608–615CrossRefPubMed
50.
Zurück zum Zitat Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189:1120–1127CrossRefPubMed Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189:1120–1127CrossRefPubMed
51.
Zurück zum Zitat C.L. Kosary (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina, Semin Surg Oncol, 10 31–46CrossRefPubMed C.L. Kosary (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina, Semin Surg Oncol, 10 31–46CrossRefPubMed
53.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National Heart Lung, Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, N.H.B.P.E.P.C. Committee (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572CrossRefPubMed Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National Heart Lung, Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, N.H.B.P.E.P.C. Committee (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572CrossRefPubMed
54.
Zurück zum Zitat Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K, C.B.O.C.O.U.o.t.B.C.C. Agency (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251CrossRefPubMed Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K, C.B.O.C.O.U.o.t.B.C.C. Agency (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251CrossRefPubMed
55.
Zurück zum Zitat Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Kobel M, Lurie G, Thompson PJ, Carney ME, Moysich K, Edwards R, Bunker C, Jensen A, Hogdall E, Cramer DW, Vitonis AF, Olson SH, King M, Chandran U, Lissowska J, Garcia-Closas M, Yang H, Webb PM, Schildkraut JM, Goodman MT, Risch HA (2013) Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5342 cases and 10,358 controls from the ovarian cancer association consortium. BMC Cancer 13:28CrossRefPubMedPubMedCentral Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Kobel M, Lurie G, Thompson PJ, Carney ME, Moysich K, Edwards R, Bunker C, Jensen A, Hogdall E, Cramer DW, Vitonis AF, Olson SH, King M, Chandran U, Lissowska J, Garcia-Closas M, Yang H, Webb PM, Schildkraut JM, Goodman MT, Risch HA (2013) Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5342 cases and 10,358 controls from the ovarian cancer association consortium. BMC Cancer 13:28CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat Müssig K, Häring HU, Insulin signal transduction in normal cells and its role in carcinogenesis. (2010) Exp Clin Endocrinol Diabetes 118:356–359CrossRefPubMed Müssig K, Häring HU, Insulin signal transduction in normal cells and its role in carcinogenesis. (2010) Exp Clin Endocrinol Diabetes 118:356–359CrossRefPubMed
57.
Zurück zum Zitat Draznin B (2010) Mitogenic action of insulin: friend, foe or ‘frenemy’? Diabetologia 53:229–233CrossRefPubMed Draznin B (2010) Mitogenic action of insulin: friend, foe or ‘frenemy’? Diabetologia 53:229–233CrossRefPubMed
58.
Zurück zum Zitat Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119:61–67CrossRefPubMedPubMedCentral Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119:61–67CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Kurman RJ, Shih IM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42:918–931CrossRefPubMedPubMedCentral Kurman RJ, Shih IM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42:918–931CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Ruterbusch JJ, Ali-Fehmi R, Olson SH, Sealy-Jefferson S, Rybicki BA, Hensley-Alford S, Elshaikh MA, Gaba AR, Schultz D, Munkarah AR, Cote ML (2014) The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am J Obstet Gynecol 211:627.e621-629CrossRef Ruterbusch JJ, Ali-Fehmi R, Olson SH, Sealy-Jefferson S, Rybicki BA, Hensley-Alford S, Elshaikh MA, Gaba AR, Schultz D, Munkarah AR, Cote ML (2014) The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am J Obstet Gynecol 211:627.e621-629CrossRef
61.
Zurück zum Zitat Olson SH, Atoria CL, Cote ML, Cook LS, Rastogi R, Soslow RA, Brown CL, Elkin EB (2012) The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev 21:753–760CrossRefPubMed Olson SH, Atoria CL, Cote ML, Cook LS, Rastogi R, Soslow RA, Brown CL, Elkin EB (2012) The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev 21:753–760CrossRefPubMed
62.
Zurück zum Zitat Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J, A.S. Group, N.-C.S. Group, E.-G.S. Group (2013) Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol 129:463–466CrossRefPubMed Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J, A.S. Group, N.-C.S. Group, E.-G.S. Group (2013) Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol 129:463–466CrossRefPubMed
63.
Zurück zum Zitat Schmidt SA, Schmidt M (2016) Beta-blockers and improved survival from ovarian cancer: new miracle treatment or another case of immortal person-time bias? Cancer 122:324–325CrossRefPubMed Schmidt SA, Schmidt M (2016) Beta-blockers and improved survival from ovarian cancer: new miracle treatment or another case of immortal person-time bias? Cancer 122:324–325CrossRefPubMed
64.
Zurück zum Zitat Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS (2016) Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Int J Cancer 139:291–299CrossRefPubMed Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS (2016) Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Int J Cancer 139:291–299CrossRefPubMed
65.
Zurück zum Zitat Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, Nelapalli NK, Min Y, Tun KD, Jamallulail SI, Rawal AK, Ramanujam R, Yedla RN, Kandregula DK, Argi A, Peela LT (2015) A review on prescribing patterns of antihypertensive drugs. Clin Hypertens 22:7CrossRefPubMed Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, Nelapalli NK, Min Y, Tun KD, Jamallulail SI, Rawal AK, Ramanujam R, Yedla RN, Kandregula DK, Argi A, Peela LT (2015) A review on prescribing patterns of antihypertensive drugs. Clin Hypertens 22:7CrossRefPubMed
66.
Zurück zum Zitat Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Goodman MT, Ness RB, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode EL, Vierkant RA, Larson MC, Fridley BL, Høgdall C, Schildkraut JM, Weber RP, Cramer DW, Terry KL, Bandera EV, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang HP, Brinton LA, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Webb PM, A.O.C.S. Group, O.C.A. Consortium (2015) Obesity and survival among women with ovarian cancer: results from the ovarian cancer association consortium. Br J Cancer 113:817–826 Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Goodman MT, Ness RB, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode EL, Vierkant RA, Larson MC, Fridley BL, Høgdall C, Schildkraut JM, Weber RP, Cramer DW, Terry KL, Bandera EV, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang HP, Brinton LA, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Webb PM, A.O.C.S. Group, O.C.A. Consortium (2015) Obesity and survival among women with ovarian cancer: results from the ovarian cancer association consortium. Br J Cancer 113:817–826
67.
Zurück zum Zitat Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB, Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the ovarian cancer association consortium. Br J Cancer, (2016) Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB, Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the ovarian cancer association consortium. Br J Cancer, (2016)
68.
Zurück zum Zitat Kasper DL, Harrison TR (2005) Harrison’s principles of internal medicine, 16th edn. McGraw-Hill, New York Kasper DL, Harrison TR (2005) Harrison’s principles of internal medicine, 16th edn. McGraw-Hill, New York
69.
Zurück zum Zitat Jorgensen TL, Teiblum S, Paludan M, Poulsen LO, Jorgensen AY, Bruun KH, Hallas J, Herrstedt J (2012) Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol 127:367–374CrossRefPubMed Jorgensen TL, Teiblum S, Paludan M, Poulsen LO, Jorgensen AY, Bruun KH, Hallas J, Herrstedt J (2012) Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol 127:367–374CrossRefPubMed
70.
Zurück zum Zitat Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ, Goodman MT, Lurie G, Chang-Claude J, Rudolph A, Kjaer SK, Jensen A, Hogdall E, Bandera EV, Olson SH, King MG, Rodriguez-Rodriguez L, Kiemeney LA, Marees T, Massuger LF, van Altena AM, Ness RB, Cramer DW, Pike MC, Pearce CL, Berchuck A, Schildkraut JM, Whittemore AS (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42:579–589CrossRefPubMedPubMedCentral Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ, Goodman MT, Lurie G, Chang-Claude J, Rudolph A, Kjaer SK, Jensen A, Hogdall E, Bandera EV, Olson SH, King MG, Rodriguez-Rodriguez L, Kiemeney LA, Marees T, Massuger LF, van Altena AM, Ness RB, Cramer DW, Pike MC, Pearce CL, Berchuck A, Schildkraut JM, Whittemore AS (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42:579–589CrossRefPubMedPubMedCentral
Metadaten
Titel
History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
verfasst von
Albina N. Minlikeeva
Jo L. Freudenheim
Rikki A. Cannioto
J. Brian Szender
Kevin H. Eng
Francesmary Modugno
Roberta B. Ness
Michael J. LaMonte
Grace Friel
Brahm H. Segal
Kunle Odunsi
Paul Mayor
Emese Zsiros
Barbara Schmalfeldt
Rüdiger Klapdor
Thilo Dӧrk
Peter Hillemanns
Linda E. Kelemen
Martin Kӧbel
Helen Steed
Anna de Fazio
Susan J. Jordan
Christina M. Nagle
Harvey A. Risch
Mary Anne Rossing
Jennifer A. Doherty
Marc T. Goodman
Robert Edwards
Keitaro Matsuo
Mika Mizuno
Beth Y. Karlan
Susanne K. Kjær
Estrid Høgdall
Allan Jensen
Joellen M. Schildkraut
Kathryn L. Terry
Daniel W. Cramer
Elisa V. Bandera
Lisa E. Paddock
Lambertus A. Kiemeney
Leon F. Massuger
Jolanta Kupryjanczyk
Andrew Berchuck
Jenny Chang-Claude
Brenda Diergaarde
Penelope M. Webb
Kirsten B. Moysich
on behalf of the Australian Ovarian Cancer Study Group
on behalf of the Ovarian Cancer Association Consortium
Publikationsdatum
14.03.2017
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2017
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0867-1

Weitere Artikel der Ausgabe 5/2017

Cancer Causes & Control 5/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.